In Cycle 0, in the absence of chemotherapy for the treatment of breast cancer, results showed that while PD response (ANC and CD34+) to a 6-mg dose of PF-06881894 was robust, the 3-mg dose was potentially subtherapeutic. This evidence concerns the gene CD34 and breast cancer.